Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)
- PMID: 9717843
- DOI: 10.1210/mend.12.8.0153
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)
Abstract
Previous studies in yeast and mammalian cells showed a functional interaction between the amino-terminal domain and the carboxy-terminal, ligand-binding domain (LBD) of the human androgen receptor (AR). In the present study, the AR subdomains involved in this in vivo interaction were determined in more detail. Cotransfection experiments in Chinese hamster ovary (CHO) cells and two-hybrid experiments in yeast revealed that two regions in the NH2-terminal domain are involved in the functional interaction with the LBD: an interacting domain at the very NH2 terminus, located between amino acid residues 3 and 36, and a second domain, essential for transactivation, located between residues 370 and 494. Substitution of glutamic acid by glutamine at position 888 (E888Q) in the AF-2 activation domain (AD) core region in the LBD, markedly decreased the interaction with the NH2-terminal domain. This mutation neither influenced hormone binding nor LBD homodimerization, suggesting a role of the AF-2 AD core region in the functional interaction between the NH2-terminal domain and the LBD. The AF-2 AD core region was also involved in the interaction with the coactivator TIF2 (transcriptional intermediary factor 2), as the E888Q mutation decreased the stimulatory effect of TIF2 on AR AF-2 activity. Cotransfection of TIF2 and the AR NH2-terminal domain expression vectors did not result in synergy between both factors in the induction of AR AF-2 activity. TIF2 highly induced AR AF-2 activity on a complex promoter [mouse mammary tumor virus (MMTV)], but it was hardly active on a minimal promoter (GRE-TATA). In contrast, the AR NH2-terminal domain induced AR AF-2 activity on both promoter constructs. These data indicate that both the AR NH2-terminal domain and the coactivator TIF2 functionally interact, either directly or indirectly, with the AF-2 AD core region in the AR-LBD, but the level of transcriptional response induced by TIF2 depends on the promoter context.
Similar articles
-
Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).Mol Endocrinol. 2000 Aug;14(8):1187-97. doi: 10.1210/mend.14.8.0499. Mol Endocrinol. 2000. PMID: 10935543
-
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor.Biochemistry. 1997 Feb 4;36(5):1052-64. doi: 10.1021/bi961775g. Biochemistry. 1997. PMID: 9033395
-
A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.Mol Cell Endocrinol. 2008 Sep 24;292(1-2):69-78. doi: 10.1016/j.mce.2008.06.016. Epub 2008 Jul 5. Mol Cell Endocrinol. 2008. PMID: 18656523
-
Structural features discriminate androgen receptor N/C terminal and coactivator interactions.Mol Cell Endocrinol. 2012 Jan 30;348(2):403-10. doi: 10.1016/j.mce.2011.03.026. Epub 2011 Jun 1. Mol Cell Endocrinol. 2012. PMID: 21664945 Free PMC article. Review.
-
Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.J Formos Med Assoc. 2000 Dec;99(12):885-94. J Formos Med Assoc. 2000. PMID: 11155740 Review.
Cited by
-
c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription.Endocrine. 2000 Aug;13(1):55-62. doi: 10.1385/ENDO:13:1:55. Endocrine. 2000. PMID: 11051047
-
Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.Assay Drug Dev Technol. 2019 Nov/Dec;17(8):364-386. doi: 10.1089/adt.2019.940. Epub 2019 Sep 6. Assay Drug Dev Technol. 2019. PMID: 31502857 Free PMC article.
-
Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.Mol Cancer Ther. 2008 Oct;7(10):3187-94. doi: 10.1158/1535-7163.MCT-08-0461. Mol Cancer Ther. 2008. PMID: 18852122 Free PMC article.
-
Hormone-activated estrogen receptors in annelid invertebrates: implications for evolution and endocrine disruption.Endocrinology. 2009 Apr;150(4):1731-8. doi: 10.1210/en.2008-1338. Epub 2008 Nov 26. Endocrinology. 2009. PMID: 19036877 Free PMC article.
-
C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction.Oncogene. 2010 Feb 4;29(5):723-38. doi: 10.1038/onc.2009.373. Epub 2009 Nov 9. Oncogene. 2010. PMID: 19901962 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials